Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fostamatinib Open Label Extension in Chronic ITP
NCT02077192Phase 3Completed
- Sponsor
- Rigel Pharmaceuticals, Inc.
- Start
- Oct 2014
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 3 trial of fostamatinib in immune thrombocytopenia (ITP), sponsored by Rigel Pharmaceuticals, Inc.. Started Oct 2014; status: completed.
02
Drugs
fostamatinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT02077192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02077192.